Genome-wide Association Study

This study has been terminated.
(Registration poor)
Sponsor:
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT01498757
First received: December 21, 2011
Last updated: May 13, 2014
Last verified: May 2014

December 21, 2011
May 13, 2014
January 2012
June 2012   (final data collection date for primary outcome measure)
Biomarkers predictive [ Time Frame: 24months ] [ Designated as safety issue: No ]
Biomarkers predictive of clinical response to Taxane or 5-fluorouracil or platinum based chemotherapy.
Same as current
Complete list of historical versions of study NCT01498757 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genome-wide Association Study
Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma

To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Esophageal squamous cell carcinoma Patients treated with Taxane/5-FU/platinum based chemotherapy.

Esophageal Squamous Cell Carcinoma.
Not Provided
Patients treated with Taxane/5-FU/platinum based chemo.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
200
Not Provided
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological confirmed esophageal squamous cell carcinoma
  • Patients treated with Taxane or 5-FU or platinum based chemotherapy.
  • provision of a signed written informed consent.

Exclusion Criteria:

  • patients not signed written informed consent.
  • patient unacceptable for study in the judgement of the investigator.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01498757
2011-05-076
No
Jeeyun Lee, Samsung Medical Center
Samsung Medical Center
Not Provided
Not Provided
Samsung Medical Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP